Pedersen lab awarded NIH R61/R33 grant — The Scintillon Research Institute

Congratulations to Associate Professor Irene Pedersen for receiving a R61/R33 grant from the NIH to study neuro-immune-vascular dynamics in preclinical neuroHIV model.
www.scintillon.org/news/neuro-h...

Oral CDK2 Inhibitor is a clinically translatable drug for cisplatin-induced hearing loss — The Scintillon Research Institute

In a collaborative study led by Dr. Tal Teitz, Associate Professor at the Scintillon Research Institute, with Drs. Jian Zuo, Yunlong Huang and colleagues from Ting Therapeutics, Inc, a selective CDK2 inhibitor was evaluated as a potential otoprotectant.
www.scintillon.org/oral-cdk2-in...

Spotlight Series on our Incubator companies: Pomelo Biosciences Inc — The Scintillon Research Institute

Pomelo Biosciences, a new incubator company at the Scintillon Research Institute working on rejuvenation and regenerative medicine. www.scintillon.org/pomelo-biosc...

Groundbreaking CAR-Microglia approach to Treat Multiple Sclerosis — The Scintillon Research Institute

Congratulations to our faculty, Dr. Brian Lawson, for receiving a Healthy Longevity Catalyst Award from the National Academy of Medicine for developing microglia with chimeric antigen receptors (CAR-microglia) as treatment for multiple sclerosis.
www.scintillon.org/brian-lawson...